stockrowLiquidia Corporation
LQDA Healthcare Drug Manufacturers Specialty & Generic
Liquidia Corporation’s revenue for fiscal 2025 (year ended December 2025) was $158.3 million, up 1,031.2% from fiscal 2024.
- Revenue
- +1,842.7%
- EPS
- +271.4%
- Free cash flow
- +270.2%
- Total debt
- −9.04%
Quarter to June 2026, against a year earlier
Follow LQDA
Alert me
Liquidia Corporation (LQDA) Revenue growth
Liquidia Corporation's revenue growth over the twelve months to 30 June 2026 was 2,233.7%, up 1202.5 percentage points from fiscal 2025 (1,031.2%). Over the past ten years it has ranged from −90.8% (fiscal 2020) to 1,996.7% (fiscal 2021); the current reading is higher than 88% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 5.22% and above the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 1,031.2% | 1,051.15 |
| FY2024 | −20.0% | (29.72) |
| FY2023 | 9.75% | (14.23) |
| FY2022 | 24.0% | 0.00 |
| FY2022 | 24.0% | (1,613.85) |
| FY2021 | 1,637.8% | (358.90) |
| FY2021 | 1,996.7% | 2,087.57 |
| FY2020 | −90.8% | 0.00 |
| FY2020 | −90.8% | (289.03) |
| FY2019 | 198.2% | 0.00 |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Jun 2026 | 1,842.7% | (2,315.76) |
| Mar 2026 | 4,158.5% | 1,103.84 |
| Dec 2025 | 3,054.7% | 1,932.93 |
| Sep 2025 | 1,121.7% | 980.21 |
| 24 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| LQDA Liquidia Corporation | 2,233.7% |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | 245.2% |
| HIMS Hims & Hers Health, Inc. compare | 28.0% |
| SUPN Indivior Pharmaceuticals Inc. compare | 16.4% |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | 8.88% |
| PBH Prestige Consumer Healthcare Inc. compare | 5.10% |
| LNTH Lantheus Holdings, Inc. compare | 2.38% |
| AMLX Amylyx Pharmaceuticals, Inc. compare | −77.1% |
| RGC Regencell Bioscience Holdings Limited compare | — |
| Drug Manufacturers Specialty & Generic industry median | 5.22% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on LQDA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement